



## **Nyxoid and Mundipharma**

Nyxoid (intranasal naloxone) is a prescription medicine approved for use as an emergency therapy for the treatment of known or suspected overdose, including illicit drugs such as heroin – a leading cause of overdose death<sup>1</sup>. Its method of administration – intranasally, rather than by injection – allows for reversal of overdoses by people with no medical training. This provides a new option for treating opioid overdoses, including in settings where the use of needles is either unacceptable or inconvenient (for example in prisons and other high-security environments).

In Europe, the Mundipharma network of independent associated companies has invested over €20 million in the research and development of this alternative route of administration for naloxone. The product was developed with the goal of contributing to addressing the issue of opioid overdose, particularly those driven by the use of illegal heroin. Mundipharma provides Nyxoid at cost price; generating no profit from its sale.

As a pharmaceutical organisation that brings value-added medicines to European countries, Mundipharma is working closely with third-party charities and organisations in the field of addiction to identify the best possible way to make Nyxoid available to patients and caregivers who may benefit from it.

---

<sup>1</sup> European Monitoring Centre for Drugs and Drug Addiction (2019), Drug-related deaths and mortality in Europe: update from the EMCDDA expert network, Publications Office of the European Union, Luxembourg. P20.